argenx NV ADR (ARGX) Stock Analysis

    $ARGX · HEALTHCARE · BIOTECHNOLOGY

    argenx NV ADR (ARGX), a BIOTECHNOLOGY company, has a market capitalization of about $55.00B and trades at 32.5x trailing earnings.

    Price

    $922.85

    Market cap

    $55.00B

    P/E ratio

    32.5x

    Dividend yield

    —

    About argenx NV ADR

    argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

    How StockWorthy values ARGX

    StockWorthy forecasts argenx NV ADR's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from ARGX's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.

    Related stocks

    Moderna Inc$MRNARegeneron Pharmaceuticals Inc$REGNVivoSim Labs, Inc.$VIVS

    See ARGX's Fair Value

    Create a free account to view argenx NV ADR's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.

    Create Free AccountSign In